Document:

ex10-13.htm

    Exhibit
10.13

     

    FOURTH
AMENDMENT

    TO

    LICENSE
AGREEMENT

    

    THIS FOURTH AMENDMENT TO THE LICENSE
AGREEMENT (the “Amendment”), is entered into as of the 20th day of June
2008 and made effective as of the Signing Date (for purposes of this Amendment,
such term shall have the meaning set forth in that certain Master Termination
Agreement of even date herewith among the parties hereto (the “Master
Termination Agreement”), by and between The Trustees of Columbia University in
the City of New York, a New York corporation (“Columbia”), and Omnimmune Corp.,
a Texas corporation (the “Company”) (together, Columbia and Company shall be
referred to as the “Parties”).  For purposes of this Amendment, the
phrase “License Agreement” shall mean that certain License Agreement entered
into by and between the Columbia and Company as of the 1st day of
February 2005, as amended March 29, 2005; June 10, 2005 and January 31, 2007;
and unless otherwise defined herein, capitalized terms and phrases shall have
the meaning ascribed thereto in the License Agreement.

    

    WHEREAS, the Company has
requested, and Columbia has agreed, to amend the License Agreement upon the
terms and conditions set forth in this Amendment;

    

    NOW THEREFORE, for good and
valuable consideration, including, without limitation, the promises and the
mutual covenants contained herein, the Parties agree as follows:

    

    Section
1.  Amendments.  Effective upon the Signing Date, the
License Agreement is hereby amended as follows:

    

    
      	
              (a)  

            	
              Section
      1, entitled “Definitions,” shall be amended by deleting in its entirety
      Subsection 1a., thereof entitled “Affiliate,” and in lieu thereof, the
      following new section shall be
added:

            

    

    

    a. “Affiliate”
means, with respect to any person or entity, a person or entity that directly or
indirectly controls, is controlled by or is under common control with such
person or entity.  For purposes of this definition, “control” shall
mean beneficial ownership (direct or indirect) of more than 50% of the
outstanding voting stock or other voting rights entitled to elect directors (or
in the case of an entity that is not a corporation the election or appointment
of the management thereof).

     

    
      	
              (b)  

            	
              Section
      3, entitled “Royalties and Payments,” shall be amended as
      follows:

            

    

    

    a. In
consideration of the license granted under Section 2.a of this Agreement, the
Company shall pay to Columbia:

    

    
      	
              (i)  

            	
              a
      reimbursement in the amount of $25,000 for past patent expenses, upon the
      initial $1,000,000 of sales of Licensed Products by Company, its
      successors or Sublicensees or any of their respective Affiliates (or any
      combination thereof);

            

    

    

    
      	
              (ii)  

            	
              a
      running royalty, to be determined on a Territory (as defined below) by
      Territory basis, equal to the greater of either 1% or the Pass-Thru
      Multiple (as defined below) of Net Sales of all Licensed Products that
      involve use of Licensed Material or Licensed Information but are not
      covered by a Claim of a Licensed Patent (the “Non-Patented Products”) for
      a term of ten (10) years from the date of the First Sale of each
      Non-Patented Product; provided, however, that
      in no event shall the running royalty under this Subsection (ii) exceed
      2%; and

            

    

    

    
      	
              (iii)  

            	
               a
      running royalty, to be determined on a Territory by Territory basis, equal
      to the greatest of (1) 2%, (2) the Pass-Thru Multiple, if applicable, or
      (3) the Transaction Multiple (as defined below), if applicable, of Net
      Sales of all Licensed Products covered by a Claim of a Licensed Patent
      licensed hereunder to the Company (the “Patented Products”), for a period
      of ten (10) years from the date of First Sale of each new Patented Product
      in a Territory or the last to expire Licensed Patent in such Territory,
      whichever is longer; provided, however, that
      in no event shall the running royalty under this Subsection (iii) exceed
      4%.

            

    

    

    
      	
              (a)  

            	
              Definitions.  For
      purposes of this Section 3.a, the following term and phrases shall have
      the meaning ascribed thereto:

            

    

    

     

    
      	
              (1)  

            	
              “Acquisition”
      shall mean the initial consummation of any of the following, effected,
      directly or indirectly, in one or more transactions:  (x) any
      sale, lease, license or other transfer or disposition of all or a majority
      of the business or assets of the Company, including, without limitation,
      by means of any revenue sharing, participation or other arrangement that
      confers all or a majority of the benefits and economic indicia of
      ownership of such business or assets; or (y) any merger, consolidation,
      conversion, other business combination, share exchange, sale or other
      transfer or disposition of shares, spin-off, spin-out, contractual
      transfer of control or voting power, reorganization, recapitalization or
      other transaction or transactions involving the Company, if after giving
      effect to any such transaction or transactions described in this clause
      (y) the holders of record or beneficial owners of the voting shares of, or
      other voting interests in, the Company prior to the first such transaction
      no longer hold or own beneficially (in substantially the same percentages)
      a majority of the voting shares of, or other voting interests in, the
      Company (a “Control Shift”); provided that neither issuances by the
      Company of its capital stock (whether as an original issuance or from
      treasury shares) to investors, solely for bona fide equity financing
      purposes nor any Control Shift that may occur solely by means of (aa) the
      private placement of up to 3,200,000 Units (as such term is defined in the
      PAA (as defined below) conducted pursuant to that certain
      Placement  Agency Agreement, dated June 20, 2008, between the
      Company and New Castle Financial Services, LLC, as such agreement is in
      effect on the date hereof, and/or (bb) the merger of the Company into a
      wholly-owned subsidiary Roughneck Supplies, Inc. (the “Merger Sub”),
      pursuant to a Merger Agreement between the Company and Roughneck Supplies,
      Inc. (or any successor thereof) and the Merger Sub., substantially upon
      the terms disclosed in the draft Confidential Private Placement Memorandum
      with respect to the sale of  up to $8 million of units, furnished to
      Columbia on the date hereof, shall, in and of themselves, be deemed to be
      an Acquisition. Without limitation as to Section 20, the term “Company,”
      as used in this definition, shall include any Successor
      Issuer.

            

    

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              (2)  

            	
              “Acquisition
      Pass-Thru Multiple” shall mean the Pass- Thru Multiple required to be paid
      by Company in respect of Net Sales under any sublicense between Company
      and any person or entity that is or becomes an Acquiring Sublicensee (as
      defined below), whether or not such sublicense remains in effect following
      an Acquisition.

            

    

     

    
      	
              (3)  

            	
              “Acquiring
      Sublicensee” shall mean, any Sublicensee (including any Affiliate of any
      Sublicensee) that has entered into any Acquisition
      transaction.

            

    

     

    
      	
              (4)  

            	
              “Pass-Thru
      Multiple” shall mean the product of the Pass-Thru Percentage (as defined
      below) multiplied by the royalty rate required to be paid by any
      Sublicensee to Company on account of Net Sales of, in the case of Section
      3.a(ii) above, Non-Patented Licensed Products or, in the case of Section
      3.a(iii) above, Patented Products, as the case may be;
  and

            

    

     

    
      	
              (5)  

            	
              “Pass-Thru
      Percentage” shall mean that percentage rate as may be applicable under
      Section 3.b below, for either sublicensed therapeutics or sublicensed
      diagnostics and in effect from time to time
  thereunder.

            

    

     

    Example:  if
prior to the first animal efficacy study Company were to sublicense a Patented
Product to a pharmaceutical company in exchange for a $1,000,000 upfront license
fee and a 15% sublicense royalty on Net Sales, then, in the absence of an
Acquisition, Company would owe Columbia the following amounts

     

    A
sublicense fee on Sublicense Revenue equal to 22.5% of $1,000,000

     

    A
running royalty of the greater of 2% of Net Sales or 3.375% (22.5% x 15%) of Net
Sales.

     

    The foregoing example is provided
solely for illustration purposes.

     

    
      	
              (6)  

            	
               “Successor
      Issuer” shall mean any issuer of securities issued to holders of the
      voting shares of, or other voting interests in, the Company directly or
      indirectly in consideration for such shares of, or interests in, the
      Company.

            

    

     

    
      	
              (7)  

            	
              “Territory”
      shall mean any defined area under the jurisdiction or considered to be the
      possession of a recognized government (e.g., the area
      described as the United States of
America).

            

    

     

    
      	
              (8)  

            	
              “Transaction
      Multiple” shall mean the greater of
either:

            

    

     

    
      	
              a.  

            	
              the
      Acquisition Pass-Thru Multiple; or

            

    

     

    
      	
              b.  

            	
              in
      the case of an Acquisition other than by an Acquiring Sublicensee, three
      percent (3%) of Net Sales of Patented Products sold for therapeutic
      purposes (whether or not such products are also sold for diagnostic
      purposes); provided, however, that
      in the case where the Acquisition occurs at a point in time where the
      Pass-Thru Percentage of 12.5% is applicable, then in such case, three
      percent (3%) shall be reduced to two and one-half percent
      (2.5%)).

            

    

     

    
      	
              (b)  

            	
              If
      more than one Licensed Patent covers a Licensed Product, no additional
      royalties will be paid by Company than if the Licensed Product is covered
      by one Licensed Patent.

            

    

    

    
      	
              (c)  

            	
              If,
      after review at any stage of prosecution, Company and Columbia amend this
      Agreement in writing that all claims issued or pending either do not cover
      a Licensed Product, or are deemed unpatentable, then the royalty to
      Columbia under Section 3a(ii) hereof shall be reduced to one percent (1%)
      of Net Sales on such Licensed Product.  Notwithstanding the
      foregoing, if a patent subsequently issues from such applications, then
      the royalty due to Columbia shall return to the original two percent (2%)
      of Net Sales on such Licensed Product, beginning on the date of such
      issue.

            

    

    

    b.           For
the avoidance of doubt with respect to the royalties to be paid by Licensee
under Sections 3a(ii) and (iii) of this Agreement, if Licensee
owes  running royalties under either such Section with respect to Net
Sales by a Sublicensee and Net Sales by Licensee itself, Licensee owes the
royalties at the same “greatest of” running royalty rate on all such sales
(prior to giving effect to Section 3c), notwithstanding that the definitions of
“Pass-Through Multiple” and “Transaction Multiple” (and any underlying
definitions) are defined on the basis of Sublicensee or Licensee
transactions.  In addition, on all other gross revenues to the extent
included in Sublicense Revenue as defined above in Section 1q (other than
royalties on Net Sales), fees, payments and consideration, or any part thereof,
received by Company from Sublicensee as full or partial consideration for the
grant of any sublicense by Company pursuant to Section 2.b, the Company shall
pay to Columbia a percentage of Sublicense Revenue received by the Company
and/or its Affiliates from its Sublicensees according to the following
schedule:

     

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    From sublicensed
therapeutics:

    

    22.5%
with respect to a sublicense entered into before the first animal efficacy study
of the Licensed Products;

    

    17.5%
with respect to a sublicense entered into after first animal efficacy study of
the Licensed Products; or

    

    12.5%
with respect to a sublicense entered into after first human clinical trial of
the Licensed Products;

    

    From sublicensed
diagnostics:

    

    17.5%
with respect to a sublicense entered into before diagnostic clinical
trial of the Licensed Products; or

     

    

    12.5%
with respect to a sublicense entered into after diagnostic clinical trial of the
Licensed Products.

    

    For the
avoidance of doubt, in the event any Sublicense Revenue derives from a Licensed
Product sold for both diagnostic and therapeutic purposes, then such product
shall be deemed to be both a sublicensed therapeutic and a sublicensed
diagnostic, and the Company shall pay Columbia with respect to all Sublicense
Revenue derived from such Licensed Product the greater of the two otherwise
applicable percentages in this Section 3.b with respect to diagnostics and
therapeutics.

    

    c.           Notwithstanding
any provision of this Agreement to the contrary, the amount of any running
royalties in excess of 1% payable by Company under Section 3.a(ii)
in  respect of Net Sales of any Licensed Product shall be reduced by
fifty percent (50%) of any running royalty payments made by the Company to third
parties in respect of know how or other proprietary rights or information
involved in the use of such Licensed Product, and the amount of any running
royalties in excess of 2% payable by Company under Section 3.a(iii) in respect
of Net Sales of any Licensed Product shall be reduced, in any Territory, by
fifty percent (50%) of any running royalty payments made by Company to third
parties in respect of Claims covering such Licensed Product in such Territory,
but only if and to the extent that such know how or other proprietary rights or
information or patent rights, as applicable, are licensed after the Signing Date
from such third parties by Company and are necessary to make, use, offer for
sale, sell or import such Licensed Product (but excluding, without limitation,
any third-party licenses related to packaging or similar uses).

     

    d.           Minimum
Annual Royalties -  Company shall pay to Columbia minimum royalties
for sales of Licensed Products  according to the following schedule,
all of which payments shall be credited towards and offset against royalties and
payments due with respect to  Sublicense Revenue before any such
payments are due to Columbia:

    

    
      	
               
      

            	
              (i)

            	
              $37,500
      on each anniversary after the First Sale of the first Licensed Product
      based on diagnostic purpose; and

            

    

    

    
      	
               
      

            	
              (ii)

            	
              $112,500,000
      on each anniversary after the First Sale of the first Licensed Product
      based on therapeutic purpose.

            

    

    

    
      	
               
      

            	
              (iii)

            	
              For
      the avoidance of doubt, in the event a product is sold for both diagnostic
      purposes and therapeutic purposes, then both the payments under Sections
      3.d(i) and 3.d(ii) are due.

            

    

    

    e.           Licensed
Product(s) Derived From More Than One Licensed Patent - If a Licensed Product is
derived from more than one Licensed Patent and/or uses more than one Licensed
Material, Company is obligated to pay only one royalty to Columbia, the highest
royalty applicable.

    

    f.           License
Maintenance Fees - Company shall pay annual license maintenance fees according
to the schedule below:

    

    $52,500 on or before May 1,
2009;

    

    $75,000
on or before May 1, 2010; and

    

    $60,000
each first of May thereafter.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
 

    The
foregoing maintenance fees shall be due and payable until Company pays Columbia
the minimum royalties under Section 3.d(i) and 3.d(ii) hereof on an annual
basis.

    

    g.           Milestone
Payment.  Upon and coincident with the date on which a New Drug
Application (“NDA”) for a Licensed Product is granted by the FDA (as such
process is contemplated in Section 505 of the Federal Food, Drug & Cosmetic
Act) or a similar approval is granted for a Licensed Product in any Territory in
which a Licensed Product is covered by a Claim of a Licensed Patent, Company
shall pay Columbia the amount of $500,000.

     

    (b)           Section
6, entitled “Best Efforts,” shall be amended as follows:

    

    
      	
              (1)  

            	
              Subsection
      6(a)(i) shall be amended by deleting the date “February 1, 2008,” and in
      lieu thereof adding the date “September 1,
  2009”;

            

    

    

    
      	
              (2)  

            	
              Subsection
      6(a)(ii) shall be amended by deleting the date “February 1, 2007,” and in
      lieu thereof adding the date “September 1,
  2009”;

            

    

    

    
      	
              (3)  

            	
              Subsection
      6(a)(iii) shall be amended by deleting the date “February 1, 2010,” and in
      lieu thereof adding the date “August 1,
2010”;

            

    

    

    
      	
              (4)  

            	
              Subsection
      6(a)(iv)(a) shall be amended by deleting the date “February 1, 2008,” and
      in lieu thereof adding the date “September 1,
  2009”;

            

    

    

    
      	
              (5)  

            	
              Subsection
      6(a)(iv)(b) shall be amended by deleting the date “February 1, 2010,” and
      in lieu thereof adding the date “February 1,
  2011”;

            

    

    

    
      	
              (6)  

            	
              Subsection
      6(a)(iv)(c) shall be amended by deleting the date “February 1, 2011,” and
      in lieu thereof adding the date “February 1,
  2012”;

            

    

    

    
      	
              (7)  

            	
              Subsection
      6(a)(v)(a) shall be amended by deleting the dates “February 1, 2008” and
      “February 1, 2010,” and in lieu thereof adding the dates “February 1,
      2011” and February 1, 2012,”
respectively;

            

    

    

    
      	
              (8)  

            	
              Subsection
      6(a)(v)(b) shall be amended by deleting the date “February 1, 2010,” and
      in lieu thereof adding the date “February 1,
  2012”;

            

    

    

    
      	
              (9)  

            	
              Subsection
      6(a)(v)(c) shall be amended by deleting the date “February 1, 2011,” and
      in lieu thereof adding the date “February 1, 2014”;
  and

            

    

    

    
      	
              (10)  

            	
              Subsection
      6(a)(v)(d) shall be amended by deleting the date “February 1, 2013,” and
      in lieu thereof adding the date “February 1, 2016”;
  and

            

    

    

    
      	
              (d)  

            	
              Section
      16, entitled “Breach and Cure” shall be amended to delete therefrom in its
      entirety Subsection 16(a)(iii).

            

    

    

    
      	
              (e)  

            	
              Section
      17, entitled “Term of Agreement,” shall be amended to delete therefrom in
      its entirety Subsection 17(a) and, in lieu thereof, the following new
      Subsection 17(a) shall be added:

            

    

    

    This
Agreement shall be effective as of the date first recited above and shall
continue in full force and effect until its expiration or termination in
accordance with this Section 17.

    

    Section
2.                      This
Amendment shall not be effective until the Signing Date, and shall be of no
force and effect unless the Signing Date occurs on or prior to August 1,
2008.  Each of the Parties to this Amendment acknowledge and agree
that, except as modified hereby, all of the terms and provisions of the License
Agreement shall remain in full force and effect.

    

     

    Section
3.                      This
Amendment and the License Agreement shall constitute the entire agreement
between the parties with respect to the subject matter hereof and supersede all
prior or contemporaneous agreements and understandings among the parties with
respect thereto.  The foregoing is without limitation as to the effect
of the Fourth Amendment and the Termination Agreement (Stockholders
Agreement).  No addition to or modification of any provision of this
Agreement shall be binding upon any party hereto unless made in writing and
signed by all parties hereto.

     

    Section
4.                      This
Amendment may be executed in any number of counterparts, each of which shall be
deemed to be an original as against any party whose signature appears thereon,
and all of which shall together constitute one and the same
instrument.  Delivery of an executed counterpart of a signature page
to this Amendment by facsimile or by electronic mail shall be effective as
delivery of a manually executed counterpart hereof.  If any portion of
this Amendment or application thereof is held invalid, the invalidity shall not
affect other provisions of this Amendment that can be given effect without the
invalid provision or application and, to this end, the provisions of this
Amendment are declared to be severable.

    

    Section
5.                      This
Amendment shall be binding upon and shall inure to the benefit of the Parties
hereto and their respective successors and assigns in accordance with Section 20
of the License.

    

    Section
6.                      Should
a conflict arise or otherwise exist between the terms and conditions of the
License Agreement and this Amendment or any interpretation thereof, each of the
Parties agree that the terms and conditions of this Amendment shall
prevail.

     

    [Remainder
of this page intentionally left blank.]

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    

    IN WITNESS WHEREOF, the
Parties have executed this Amendment as of the date first above
written.

    

    Columbia

    

    The
Trustees of Columbia University in the City of New York, a New York
corporation

    

    By: /s/ Orin
Herskowitz

    Name: Orin
Herskowitz

    Title: Executive Director, Science
and Technology Ventures

    

    

    

    COMPANY

    

    Omnimmune
Corp., a Texas corporation

    

    

    By:/s/ Harris A.
Lichtenstein                                                                           

    Name: Harris A.
Lichtenstein

    Title: President and
CEOex10-14.htm

    
      Exhibit
10.14

       

      EXCLUSIVE
LICENSE AGREEMENT

    

     

    THIS EXCLUSIVE LICENSE AGREEMENT
(the "Agreement"), is entered into as of the first day of November 2007
(the "Effective Date"), by and among Institut Gustave Roussy, a private cancer
research and treatment non-profit making center incorporated in the Republic of
France ("IGR"),
IGR&D, S.A., a company incorporated in the Republic of France, Creteil
(societe anonyme au capital de 200 200 euro, immatriculee au Registre du
Commerce et des Societes de Creteil sous le numero B 432 439 776) and whose
registered office is 39, rue Camille Desmoulins – 94805 VILLEJUIF Cedex
("IGR&D"), represented by Isabelle Pelletier Bressac, managing director
(hereafter "IGR&D"), and Omnimmune Corp., a Texas corporation located at
4600 Post Oak Place, Suite 352, Houston, Texas 77027, U.S.A. (hereinafter
"Omnimmune").  IGR&D and Omnimmune may also be hereinafter jointly
referred to as the "Parties" and individually referred to as the
"Party."

     

    WHEREAS, IGR is the sole and
exclusive owner of the Inventions (as defined below);

     

    WHEREAS, Omnimmune is
interested in exploiting and commercializing the Inventions, which relate to
monoclonal antibodies, cell lines, genetic sequences and gene-based products
that target and are related to a hormone called human chorionic
gonadotropin (hCG);

     

    WHEREAS, IGR has granted all
of its right, title and interest to the Invention to IGR&D, its technology
transfer Affiliate, meaning that IGR&D is duly authorized to negotiate and
to license the rights under the Licensed Patents; and

     

    WHEREAS, Omnimmune desires,
and IGR&D has agreed to license the rights under the Licensed Patents
pursuant to the terms of this Agreement.

     

    NOW, THEREFORE, in
consideration of the mutual promises contained herein and other good and
valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, and with the intent to be legally bound hereby, the Parties hereto
agree as follows:

     

    1.           Definitions.

     

    
      	
              a.  

            	
              Affiliate shall
      mean, with respect to a particular Party, a person, corporation,
      partnership, or other entity that controls, is controlled by or is under
      common control with such Party. For the purposes of the definition, the
      word "control" (including, with correlative meaning, the terms "controlled
      by" or "under the common control with") means the actual power, either
      directly or indirectly through one or more intermediaries, to direct or
      cause the direction of the management and policies of such entity, whether
      by the ownership of at least fifty percent (50%) of the voting stock of
      such entity, or by contract or
otherwise.

            

    

     

    
      	
              b.  

            	
              Confidential
      Information shall mean all confidential or proprietary
      materials or information designated as such in writing by the party
      disclosing such information (the "Disclosing Party"), whether by letter or
      by the use of an appropriate proprietary stamp or legend, prior to or at
      the time any confidential or proprietary materials or information is
      disclosed by Disclosing Party to the receiving party (the
      "Recipient").  Notwithstanding the foregoing, information or
      materials which are orally or visually disclosed to Recipient by
      Disclosing Party, or are disclosed in writing or other tangible form
      without an appropriate letter, proprietary stamp or legend, shall
      constitute Confidential Information if Disclosing Party, within
      thirty (30) days after such disclosure, delivers to Recipient a
      written document or documents describing such information or materials and
      referencing the place and date of such oral, visual or written or other
      tangible disclosure, and the names of the employees or officers of
      Recipient to whom such disclosure was
made.

            

    

     

    
      	
              c.  

            	
              Designative
      Representatives shall mean employees, consultants and advisors of
      the Parties or any Affiliate thereof to whom Confidential Information is
      disclosed only on a “need-to-know” basis and who are directed and required
      to both maintain the disclosed Confidential Information in strict
      confidence and exclusively use such Confidential Information solely for
      the purposes expressly permitted under this
  Agreement.

            

    

     

    
      	
              d.  

            	
              Field shall
      mean all fields of use.

            

    

     

    
      	
              e.  

            	
              First Commercial
      Sale shall mean the first sale of a Licensed Product by Omnimmune
      or an Affiliate or sublicensee of Omnimmune to a Third Party in a country
      following regulatory approval of such Licensed Product in that country or,
      if no such regulatory approval or similar marketing approval is required,
      the date upon which such Licensed Product is first commercially launched
      in such country.

            

    

     

    
      	
              f.  

            	
              IND shall mean
      an application submitted to a regulatory authority to initiate human
      clinical trials, including (1) an Investigational New Drug application or
      any successor application or procedure filed with the FDA or any foreign
      equivalent thereof, and (2) all supplements and amendments that may be
      filed with respect to the
foregoing.

            

    

     

    
      	
              g.  

            	
              In
      Vitro
      Diagnostic 510(k) shall mean a premarket notification submission to
      the United States ("US") Food and Drug Administration (FDA) or similar
      governmental agency in jurisdictions other than the US.  The
      submission must provide evidence that the device is accurate, safe,
      effective and substantially equivalent to a device legally marketed in the
      United States.

            

    

     

    
      	
              h.  

            	
              In
      Vitro
      Diagnostic Clinical Study shall mean in order to demonstrate
      clinical use as an aid in cancer detection, evaluations of hCG antibodies,
      hCG genes or gene products to demonstrate that hCG as a tumor marker is a
      significant indicator of the presence of cancerous
  cells.

            

    

     

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              i.  

            	
              In
      Vitro
      Diagnostic Compilation and Submission of a 510(k)
      shall mean a premarket notification or application submitted to the FDA or
      similar governmental agency in jurisdictions other than the US, the
      purpose of which is to demonstrate that the medical device to be marketed
      is substantially equivalent (SE) to a legally marketed device that was or
      is currently on the U.S. market.  The manufacturer may not place
      their device into U.S. commerce until they receive a marketing
      clearance/SE letter from the FDA.

            

    

     

    
      	
              j.  

            	
              Improvements
      shall mean any improvement, addition, enhancement, modification,
      development, invention, alteration and/or technical advance or other
      discovery, whether patentable or not, the exploitation of which is
      dependent on or would infringe (but for a license thereto by IGR or
      IGR&D (as the case may be)) at least one Valid Claim contained in the
      Licensed Patents.

            

    

     

    
      	
              k.  

            	
              Licensed
      Information shall mean know-how, research and development,
      analyses, notes and other such records, procedures, assay and other
      methods, formulae, indices, techniques, drawings, improvements, software
      code, algorithms, data management or interpretive systems, processes,
      protocols, genetic or other libraries, designs, concepts, models,
      inventions, discoveries, copyrights, trade secrets and other intellectual
      property, whether proprietary or not, including, without limitation, data
      generated in pre-clinical and clinical studies, relating to the Licensed
      Technology, along with any and all documents and other records (electronic
      or otherwise) relating thereto, including, without limitation, any and all
      results of experiments,
      clinical trials and studies relating to the claims made in the Licensed
      Patents, and owned by IGR or any Affiliate thereof or to which IGR or any
      Affiliate thereof may have any rights of
use.

            

    

     

    
      	
              l.  

            	
              Licensed
      Material shall mean the tangible or physical materials necessary
      for the effective exercise of the Licensed Patents or any other uses and
      such other materials as are routinely produced through use of the original
      materials, including, without limitation, the materials listed on
      Attachment A hereto and any and all other cell lines, samples, primers,
      monoclonal antibodies, reagents, DNA or RNA replicated from isolated DNA
      or RNA, recombinant proteins produced through use of isolated DNA or RNA,
      substances routinely purified from a source material included in the
      original materials (such as recombinant proteins isolated from a cell
      extract or supernatant by non-proprietary affinity purification methods)
      and any other materials relating to the Licensed Patents, together with
      any progeny, mutants and unmodified derivatives thereof, and owned by
      IGR&D or any Affiliate thereof or to which IGR&D or any Affiliate
      thereof may have any rights of use.

            

    

     

    
      	
              m.  

            	
              Licensed
      Patents shall mean the following United States
      patents:  US 6194154 entitled “Malignant human cell
      transformation detection method” claiming the priority date March 4, 1996,
      from the French patent application FR9602683, and US 6514708 entitled
      “Process for detecting the malignant transformation of human cells”
      claiming the priority date March 4, 1996, from the French patent
      application FR9602683 (the “Original Licensed Patents”), and any and all
      patent applications and patents issued thereon in connection with any and
      all Improvements, and

            

    

     

    (1) all
continuations, divisions, continuations-in-part, reissues, re-examinations, and
extensions thereof, and any patents issuing therefrom that are owned or
controlled, in whole or in part, by IGR, including, without limitation, any and
all provisional patent applications and Patent Cooperation Treaty (PCT) patent
applications, all divisions and continuations of these applications, all patents
issuing from such applications, divisions, and continuations, and any reissues,
reexaminations, and extensions of all such patents;

     

    (2) to
the extent that the following contain one or more claims directed to that
described in subsection (1) immediately
above:  (i) continuations-in-part of (1) above;
(ii) all divisions and continuations of these continuations-in-part;
(iii) all patents issuing from such continuations-in-part, divisions, and
continuations; and (iv) any reissues, reexaminations, and extensions of all
such patents; and

     

    (3) to
the extent that the following contain one or more claims directed to that
described in subsection (1) immediately above: all counterpart foreign
applications and patents related to that described in subsections (1) and
(2) above, including those listed in Appendix A.

     

    
      	
              n.  

            	
              Licensed
      Process shall mean any process, service, formulae, algorithm, data
      management or other systems, methodology or similar capability that is
      covered in whole or in part by an issued, unexpired claim or a pending
      claim contained in the Licensed Patents, including, without limitation,
      the process or methodology for detecting malignant transformation of human
      cells and its applications for diagnosing and monitoring cancer patients
      and for developing cancer
prognosis.

            

    

     

    
      	
              o.  

            	
              Licensed
      Product shall mean any product or part thereof that (1) is covered
      in whole or in part by an issued, unexpired claim or a pending claim
      contained in the Licensed Patents in the country in which any such product
      or part thereof is made, used or sold; (2) is manufactured by using a
      process that is covered in whole or in part by an issued, unexpired claim
      or a pending claim contained in the Licensed Patents, in any country in
      which any such process is used or in which any such product is used or
      sold or (3) is developed or manufactured from the Licensed Material or
      Licensed Information, but which is not covered under clauses (1) and (2)
      above.

            

    

     

    
      	
              p.  

            	
              Licensed
      Technology shall mean the Licensed Patents, Licensed
      Information and Licensed Materials, along with the Licensed Products and
      Licensed Processes, and any and all Improvements
  thereon.

            

    

     

    
      	
              q.  

            	
              NDA shall mean
      an application submitted to a regulatory authority for marketing approval
      of a product, including (1) a New Drug Application, Product License
      Application or Biologics License Application filed with the FDA or any
      successor applications or procedures, or any foreign equivalent thereof,
      and (2) all supplements and amendments that may be filed with respect to
      the foregoing.

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
    

    
      
         

        
          	r.  	

                  Net Sales shall mean with
      respect to the Licensed Technology, the gross revenue received by
      Omnimmune or its Affiliates (in the case where any such Affiliate is not a
      sublicensee) for the sale of the Licensed Products or
      Licensed Processes during the term of this Agreement to a Third
      Party, less allowances for the following
items:

                

        

         

      

    

    (1)
trade, quantity and cash discounts actually allowed;

     

    (2)
discounts, refunds, rebates, charge backs, retroactive price adjustments, and
any other allowances actually granted which effectively reduce the net selling
price;

     

    (3)
product returns and allowances actually granted;

     

    (4) any
tax, tariff or duty imposed on the production, sale, transportation, delivery or
use of the product (excluding federal, state or local taxes based on
income);

     

    (5)
freight, postage, shipping, transportation, customs duties, excises and
insurance charges actually allowed or paid for delivery of Licensed Products, to
the extent billed; and

     

    (6)  a
reasonable reserve for bad debts accrued in accordance with Omnimmune's standard
accounting practices applied consistently across its business.

     

    For the
avoidance of doubt, Net Sales (or performance, as the case may be) of Licensed
Technology shall not include Transfer Pricing Amounts. Net Sales for Licensed
Products and Licensed Processes sold by Omnimmune or its Affiliate(s) as a unit
in conjunction with other licensed processes or
licensed products will be determined pro rata in accordance with the respective
stand-alone price or value of such licensed products and/or licensed
processes.

     

    
      	
              s.  

            	
              Phase I Study
      shall mean a study of a product in human volunteers or patients, the
      purpose of which is the preliminary determination of safety and
      tolerability of a dosing regime and for which there are no primary
      endpoints (as recognized by FDA) in the protocol relating to
      efficacy.

            

    

     

    
      	
              t.  

            	
              Phase II Study
      shall mean (1) a dose exploration, dose response, duration of effect,
      kinetics, dynamic relationship or preliminary efficacy and safety study of
      a product in the target patient population, or (2) a controlled dose
      ranging clinical trial to evaluate further the efficacy and safety of a
      product in the target patient population and to define the optimal dosing
      regimen.

            

    

     

    
      	
              u.  

            	
              Phase III Study
      shall mean a controlled pivotal clinical study of a product that is
      prospectively designed to demonstrate statistically whether such product
      is effective and safe for use in a particular indication in a manner
      sufficient to obtain regulatory approval to market such
      product.

            

    

     

    
      	
              v.  

            	
              Sublicense
      Revenue shall mean, except as otherwise provided herein, all
      amounts actually received by Omnimmune or any Affiliate thereof (if such
      Affiliate is the sublicensor under a sublicense) from a sublicensee on
      account of the sublicensing of all or any part of the Licensed Technology,
      including, without limitation, all sublicense fees, royalties, milestone
      payments and other fees or payments; provided, however, that
      Sublicense Revenue shall not include any amounts constituting
      (1) bona fide research and development funding, such as NIH or other
      grants, directly relating to potential Licensed Products or Licensed
      Processes, as reflected in the recipient's books and records in accordance
      with generally accepted accounting principles, including allocations for
      overhead and general and administrative costs, and (2) amounts
      reimbursed by a Third Party for payments for bona fide research and
      development activities directly relating to potential Licensed Products or
      Licensed Processes, as reflected in the recipient's books and records in
      accordance with generally accepted accounting principles including
      allocations for overhead and general and administrative
    costs.

            

    

     

    
      	
              w.  

            	
              Territory shall
      mean worldwide.

            

    

     

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    
      	
              x.

            	
              Third
      Party shall mean any
      entity other than the Parties to this Agreement and their respective
      Affiliates.

            

    

     

    
      	
              y.  

            	
              Transfer Pricing
      Amounts shall mean prices used in the transfer of materials between
      units or Affiliates or Sublicensees of the same company, at cost or cost
      plus transportation costs and only if this transfer does not result in a
      consumption, destruction or loss of activity of the Licensed
      Product.

            
	

              z.
       
 	

              Valid Claim
      shall mean a claim of any pending, or issued and unexpired Licensed Patent
      which shall not have been withdrawn, canceled, or disclaimed, nor held
      invalid by a court of competent jurisdiction in any unappealed or
      unappealable decision (after all such statutes of limitation for such
      appeal have run) in the country where the product or process was made,
      used or sold by Licensee or its
Affiliates.

            

    

     

     

    
      	
              2.  

            	
              License
      Grant

            

    

     

    
      	
              a.  

            	
              Exclusive
      License.  Subject to the terms and conditions of this
      Agreement, IGR&D grants to Omnimmune and any Affiliate thereof, an
      exclusive license in the Territory for the term of this Agreement to use
      the Licensed Patents, Licensed Material and Licensed Information (along
      with Improvements thereon), directly and indirectly, to invent,
      characterize, select, discover, make, develop, manufacture, use, sell,
      rent, lease, distribute, import, export or otherwise use the Licensed
      Products, and to practice and permit the practice of the Licensed
      Processes in the Field, with rights to sublicense to Third
      Parties.

            

    

     

    
      	
              b.  

            	
              Representations and
      Warranties.  Each of IGR and IGR&D represents and
      warrants that, except as otherwise provided in this Agreement, (1) it
      has not transferred by license or otherwise any rights in the Licensed
      Technology to any Person, (2) that each has the power and authority to
      enter into, deliver and perform its obligations under this Agreement, and
      (3) it has not knowingly taken any action or omitted to take any
      action that would result in the invalidity, reduction in scope or
      abandonment of any of the Licensed Patents.  Each of IGR and
      IGR&D further covenants that it will not knowingly or intentionally
      take or omit to take any of the actions described in the immediately
      preceding sentence.

            

    

     

    
      	
              c.  

            	
              Access to Licensed
      Information and Licensed Material.  During the term of
      this Agreement, each of IGR and IGR&D, as applicable, shall provide as
      soon as reasonably practicable, but in no event later than ten (10)
      business days following the Effective Date, Omnimmune with (1) all
      Licensed Information and Licensed Materials, and (2) a reasonable
      opportunity to discuss the Invention with IGR's research
      personnel.  Each of IGR and IGR&D shall have a continuing
      obligation during the term of this Agreement to supplement such
      disclosures to Omnimmune with current information and materials relating
      directly to the Licensed Patents, including any Improvements to Licensed
      Patents.  Omnimmune shall provide each of IGR and IGR&D with
      a Federal Express account number or an account number for another courier
      service, so that IGR or IGR&D, as applicable, may ship the Licensed
      Material to Omnimmune.

            

    

     

    
      	
              d.  

            	
              Sublicensing
      Rights.  For the term of this Agreement, IGR&D grants
      to Omnimmune the right to grant sublicenses of the Licensed Technology to
      Third Parties in the Field and throughout the Territory; provided, however, that
      (1) the sublicensee shall have agreed that any right granted thereto
      pursuant to this Subsection shall be subject to the terms and conditions
      of this Agreement, including, without limitation, Section 16(d) below; (2)
      Omnimmune will provide promptly IGR&D with information of any grant of
      any such sublicense and will provide to IGR&D, upon IGR&D’s
      request, a copy of any sublicense agreement; provided, that Omnimmune's
      obligation to provide a copy of any such sublicense shall be subject to
      applicable confidentiality obligations of Omnimmune, and any sublicense
      provided to IGR&D shall constitute Omnimmune Confidential Information;
      and (3) no such sublicense shall relieve Omnimmune of its obligations
      under this Agreement.

            

    

     

    
      	
              3.  

            	
              Royalties and Other
      Payments.

            

    

     

    
      	
               
      

            	
              a.

            	
              License Fee Upfront
      Payment.  A one-time nonrefundable and non-creditable
      license fee of one hundred twenty-five thousand euro (125,000€) as
      follows:

            

    

     

    (1)           Twenty-five
thousand euro (25,000€) shall be paid upon and coincident with the Effective
Date;

     

    (2)           Fifty
thousand euro (50,000€) shall be paid upon the first anniversary following the
Effective Date; and

     

    The
balance of fifty thousand euro (50,000€) shall be paid upon the second
anniversary of the Effective Date.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              b.  

            	
              License Maintenance
      Fees.  An annual license maintenance fees according to
      the schedule below:

            

    

     

    (1)           Ten
thousand euro (10,000€) one (1) year from the execution of this
Agreement;

     

    (2)           Twenty
thousand euro (20,000€) two (2) years from the execution of this
Agreement;

     

    (3)           Thirty-five
thousand euro (35,000€) three (3) years from the execution of this
Agreement;

     

    (4)           Fifty
thousand euro (50,000€) four (4) years and thereafter from the execution of this
Agreement.

     

    
      	
               
      

            	
              c.

            	
              Milestones

            

    

     

    (1)           In Vitro Diagnostic
Milestones.  Milestone payments for each diagnostic Licensed
Product within thirty (30) days of the following events:

     

    (i)           In
the territory of the United States and so long as the Original Licensed Patents
have not been rendered invalid or held to infringe on any other patent right as
of the due date thereof, Omnimmune shall pay IGR&D the
following:

     

    (A)           At
the commencement of an In Vitro diagnostic Clinical Study: Five thousand euro
(5,000€);

     

    (B)           Upon
compilation and Submission of a 510(k) authorization or equivalent thereto : Ten
thousand euro (10,000€); and

     

    (C)           At
the First Commercial Sale following the 510(k) authorization or equivalent
thereto:  Twenty-five thousand euro (25,000€) if the First Commercial
Sale is in the United States of America (“USA”).

     

    (ii)           If
milestones are reached in countries outside of the territory of the United
States or if the Original Licensed Patents have been rendered invalid or held to
infringe on any other patent right as of the due date thereof, Omnimmune shall
pay IGR&D the following:

     

    
      	
              (A) 

            	
              At
      the commencement of an In Vitro diagnostic Clinical Study: Two thousand
      five hundred euro (2,500€);

            

    

     

    
      	
              (B)  

            	
              Upon
      compilation and Submission of a 510(k) authorization or equivalent
      thereto: Five thousand euro (5,000€);
and

            

    

     

    
      	
              (C)  

            	
              At
      the First Commercial Sale following the 510(k) authorization or equivalent
      thereto:  Twelve thousand euro five hundred euro (12,500€) if
      the First Commercial Sale is in the United States of
      America (“USA”).

            

    

     

    (2)           Therapeutic
Milestones. Omnimmune agrees to make milestone payments to IGR&D for
each Licensed Product within thirty (30) days of the following
events:

    

    
      	
              (i)  

            	
              At
      the first entrance in Phase II Clinical Trial:  Twenty five
      thousand euro (25,000€);

            

    

    

    
      	
              (ii)  

            	
              At
      the first entrance in Phase III Clinical Trial: Seventy five thousand euro
      (75,000€);

            

    

    

    
      	
              (iii)  

            	
              At
      the first NDA submission: One hundred twenty five thousand euro
      (125,000€); and

            

    

    

    
      	
              (iv)  

            	
              At
      the First Commercial Sale:  one hundred seventy five thousand
      euro (175,000€).

            

    

     

    
 

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	
              d.  

            	
              Running
      Royalty.  In consideration of the license granted under
      this Agreement, Omnimmune shall pay to IGR&D a royalty equal to
      four percent (4%) of Net Sales in the USA and a royalty equal to two
      percent (2%) of Net Sales in the Territory outside of the USA (the
      "Running Royalty").  The Running Royalty shall be reduced, but
      not below fifty percent (50%) of the amount due prior to such
      reduction, by fifty percent (50%) of any royalty amounts, fees or
      other like payments payable to Third Parties in respect of patent rights,
      know how or other proprietary rights or information licensed from such
      Third Parties that are necessary for use of the Licensed Patents as
      contemplated in this Agreement or are incorporated into the License
      Products or Licensed Processes; provided, however, that
      said incorporation must be necessary for the commercialization of the
      License Products or Licensed Processes (i.e., improves,
      enhances or otherwise makes the commercialization thereof more
      likely).

            

    

     

    
      	
              e.  

            	
              Sublicensing
      Royalty.  In consideration of the right to sublicense to
      Third Parties granted under this Agreement, Omnimmune shall pay to
      IGR&D twenty percent (20%) of Sublicense Revenue received in the
      Territory of the USA and ten percent (10%) of Sublicense Revenue received
      elsewhere in the Territory.  The Sublicense
      Royalty shall be reduced, but not below fifty percent (50%) of the amount
      due prior to such reduction, by fifty percent (50%) of any
      royalty amounts, fees or other like payments payable to Third Parties in
      respect of patent rights, know how or other proprietary rights or
      information licensed from such Third Parties that are necessary for use of
      the Licensed Technology as contemplated in this
  Agreement.

            

    

     

    
      	
              f.  

            	
              Additional Payment
      Adjustments.  If more than one Licensed Patent covers a
      Licensed Product or Licensed Process, Omnimmune is not obligated to pay
      multiple royalties based on the fact that such Licensed Product or
      Licensed Process are covered by more than one Licensed
      Patent.  If and to the extent all claims in any pending
      application under the Licensed Patents covering a product or process are
      deemed unpatentable or either such claims or the Licensed Materials or
      Licensed Information otherwise cannot be made the subject of a patent,
      then the Running Royalty or Sublicense Royalty, as the case may be, shall
      be reduced by fifty percent (50%). Milestone payments, except for first
      commercial sale milestone payments, are non-refundable, non-creditable
      against future royalties, and are payable only once the first time a
      milestone is achieved.  First commercial sales milestones for
      diagnostic and, if any, therapeutics are fully creditable against future
      Percentage Payments.

            

    

     

    
      	
              g.  

            	
              VAT.  All
      payments pursuant to this Agreement by Omnimmune to IGR&D are
      expressed exclusive of any Value Added Tax ("VAT"), which may be
      chargeable thereon. The USA national VAT, if any, shall be paid by
      Omnimmune directly to its competent USA tax
  authority.

            

    

     

    
      	
              h.  

            	
              Withholding
      Taxes.  Withholding taxes (if any) levied by the USA tax
      authorities or a government of any country on payments made to IGR&D
      by Omnimmune hereunder shall be deducted from the royalties due by
      Omnimmune.  Omnimmune shall lend its support to IGR&D to
      avoid any double taxing and provide it upon request with any document
      necessary for this purpose. Omnimmune shall use its commercially
      reasonable efforts to help IGR&D claim exemption therefrom under any
      double taxation or similar agreement in force and shall produce to
      IGR&D proper evidence of payment of all withholding tax.

            

    

     

    
      	
              4.  

            	
              Reports
      and Payments.

            

    

     

    
      	
              a.  

            	
              Payment
      Report.  On or before the sixtieth (60th) day following
      each calendar quarterly period, Omnimmune shall submit to IGR&D a
      written report with respect to the preceding calendar quarter (the
      “Payment Report”) stating (i) Net Sales made by Omnimmune or any Affiliate
      thereof (or both) during such quarter; (ii) in the case of transfers of
      Licensed Technology by Omnimmune to an Affiliate thereof for use by any
      such Affiliate, Net Sales by Omnimmune to such Affiliate, and Net Sales by
      such Affiliate or sublicensee to Third Parties during such quarter; (iii)
      amounts accruing to, and received by, Omnimmune or any Affiliate thereof
      (or both) from any sublicensee thereof during such quarter; and (iv) a
      calculation under this Agreement of the amounts due to
      IGR&D.

            

    

     

    
      	
              b.  

            	
              Timing of
      Payment.  Simultaneously with the submission of each
      Payment Report, Omnimmune shall make payments to IGR&D of the amounts
      due for the calendar quarter covered by the Payment
  Report.

            

    

     

    
      	
              c.  

            	
              Books and
      Records.  Omnimmune shall maintain at its principal
      office usual books of account and records showing its actions under this
      Agreement.  Upon reasonable notice, such books and records shall
      be open to IGR&D at its sole cost and expense, for inspection and
      copying, during usual business hours, not more than once during any twelve
      (12) consecutive calendar month period, by an independent certified public
      accountant to whom Omnimmune has no reasonable objection.  Such
      books and records shall be open to IGR&D for two years after the
      calendar quarter to which any such Payment Report relates, for purposes of
      verifying the accuracy of the amounts paid by Omnimmune under this
      Agreement.  If such independent accountant reasonably determines
      that Omnimmune has underpaid royalties by more than five percent (5%)
      otherwise due and owing for any particular calendar quarter, Omnimmune
      will pay (subject to its right to contest the same) the costs and expenses
      reasonably and actually incurred by IGR&D in the inspection and
      copying of such calendar quarter.

            

    

     

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              5.  

            	
              Reservation
      of Rights for Research Purposes.  With
      respect to the license granted to Omnimmune, IGR reserves the right to use
      the Licensed Patents for its internal, noncommercial research
      purposes.  IGR shall obtain in advance from all of its
      researchers and other personnel who it permits to use the Licensed Patents
      for such purposes an agreement in writing (1) requiring that all
      information defined under this Agreement as Confidential Information be
      maintained in strict confidence in accordance with terms and conditions
      substantially similar to the provisions of Section 14 of this Agreement;
      (2) requiring prompt disclosure to IGR and Omnimmune of any and all
      inventions and discoveries; (3) providing for each such invention and
      discovery to be covered by appropriate patent filings; (4) requiring the
      assignment of all Improvements to Omnimmune in accordance with this
      Agreement; and (5) prohibiting the use of such Licensed Patents for
      commercial purposes; and shall inform Omnimmune in writing of the identity
      of all such Persons.  Either of IGR or IGR&D (or both as the
      case may be) shall promptly disclose such Improvements to Omnimmune and
      such Improvements shall be deemed included in the license grant hereunder
      without any further act on the part of IGR, IGR&D or Omnimmune,
      without any further payment and without duplication of payment upon
      achievement of milestones or commercialization, except that all products
      utilizing the Improvements shall be deemed to be Licensed Products or
      Licensed Process, as the case may be, and shall be subject to the royalty
      provisions set forth herein for Licensed Products and Licensed
      Process.

            

    

     

    
      	
              6.  

            	
              Best
      Efforts.  Omnimmune shall use, and shall cause its
      Affiliates and its sublicensees to use, its or their best commercially
      reasonable efforts, consistent with commercial practices standard in the
      industry and taking into account prudent scientific and business judgment
      consistent with the efforts of Omnimmune or its sublicensees devoted to
      products, kits, gene probes or antibodies of similar market potential, to
      effect introduction as soon as reasonably practicable of the Licensed
      Products or Licensed Processes into the marketplace.  No less
      often than every twelve (12) months following the execution of this
      Agreement, Omnimmune shall report in writing to IGR&D on progress made
      toward the objectives set forth in this Agreement. In the event that
      neither Omnimmune nor its Affliiates generate Net Sales or Sublicense
      Revenue within three (3) years after the Effective Date, the Licensed
      Patent rights granted by this Agreement will become non-exclusive;
      provided that Omnimmune shall be entitled to an extension of such
      exclusivity for two additional consecutive one year periods upon (1)
      notice by Omnimmune to IGR&D that Omnimmune wishes to extend the
      exclusivity period of the Licensed Patent rights, and (2) payment to
      IGR&D of twenty-five thousand euro (25,000€) for each year such
      exclusivity is extended pursuant to this Section.  If during any
      such periods of extension such sales or revenue are achieved, then the
      exclusive license granted Omnimmune shall continue for the remainder of
      the Term under this Agreement.

            

    

     

    
      	
              7.  

            	
              Patent
      Prosecution and Maintenance.  Omnimmune shall, by counsel
      it selects to whom IGR&D has no reasonable objection, prepare, file,
      prosecute and maintain all Licensed Patents in IGR’s name and in countries
      designated by Omnimmune.  Omnimmune will timely provide
      IGR&D copies of all correspondence related to reasonable Licensed
      Patent prosecution and maintenance.  IGR&D shall undertake
      timely any and all actions deemed necessary by Omnimmune to enable it to
      fulfill its obligations under this Section, including, without limitation,
      making available to it any and all researchers and information relating
      thereto.  Omnimmune will reimburse and pay the expenses IGR or
      IGR&D reasonably and actually incurs in supporting or otherwise
      cooperating with Omnimmune in filing, prosecuting and maintaining such
      Licensed Patents, including attorneys’ fees, the costs of any interference
      proceedings, reexaminations, or any other ex parte or inter partes
      administrative proceeding before patent offices, taxes, annuities, issue
      fees, working fees, maintenance fees and renewal charges; provided that
      all such expenses are subject to the prior written approval of
      Omnimmune.

            

    

     

    
      	
              8.  

            	
              Infringement.

            

    

     

    
      	
              a.  

            	
              Third Party
      Infringement of Licensed Patent
Rights.

            

    

     

    (1)           In
General.  Omnimmune and IGR&D (or IGR, if applicable) shall
promptly provide written notice to the other Party of any alleged infringement
by a Third Party of the Licensed Patents and provide such other Party with any
available evidence of such infringement.  In the event there is good
reason to believe infringement of any of the Licensed Patents is occurring,
Omnimmune will take prompt, commercially reasonable action to abate or settle
such infringement.  Omnimmune shall have the right to institute an
action in its own name, in so far as permitted by law, to abate the infringement
of the Licensed Patent and may join IGR or IGR&D as a party plaintiff, only
if without cost to IGR or IGR&D.  During the term of this
Agreement, Omnimmune shall have the right to prosecute, at its own expense and
utilizing counsel of its choice, any infringement of the Licensed
Patent.   Omnimmune shall promptly provide IGR&D copies of
all litigation pleadings ands other documents submitted to the court regarding
the infringement of the Licensed Patents.  No settlement, consent
judgment or other voluntary final disposition of any such claim of infringement
of the Licensed Patents may be entered into without the written consent of
IGR&D, which consent shall not unreasonably be withheld, delayed, denied or
conditioned.

     

    (2)           Third Party Enforcement
Costs and Recoveries.  If Omnimmune undertakes to enforce
and/or defend the Licensed Patents by litigation, Omnimmune may deduct from
payments due hereunder to IGR&D reasonable costs and legal fees incurred to
conduct such proceedings, but in no event shall any payment due in any calendar
quarter be reduced by more than fifty percent (50%) of the amount otherwise due
to IGR&D hereunder.  Any recovery by Omnimmune in such proceedings
shall first be used to reimburse Omnimmune for its reasonable costs and legal
fees incurred to conduct such proceedings and next to pay to IGR&D an amount
equal to all amounts withheld from IGR&D by Omnimmune under this Section
during the pendency of the proceedings.  The remaining balance being
divided between IGR and Omnimmune by, in the case where the recovery is based on
Omnimmune’s lost profits, determining the amount of Net Sales that would have
been required for purposes of calculating such lost profits, and then
calculating the royalty that would have otherwise been paid to IGR under this
Agreement had such Net Sales been received by Omnimmune (after taking into
account the amounts allocated under clauses (1) and (2) above); provided, however, that in no
event shall the amount payable from any such recovery exceed fifty
percent (50%) of any such lost profits, with all amounts remaining from any
such recovery being paid to or otherwise retained by Omnimmune.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    (3)            
IGR&D's Control of
Enforcement Actions.  If within six (6) months after receiving
notice of any alleged infringement of the Licensed Patents by a Third Party,
Omnimmune shall have been unsuccessful in persuading the alleged infringer to
desist, and shall not have brought and shall not be diligently prosecuting an
infringement action, or if Omnimmune shall notify IGR&D, at any time prior
thereto, of its intention not to bring suit against the alleged infringer, then
IGR&D shall have the right, but not the obligation, to prosecute, at its own
expense and utilizing counsel of its choice, any infringement of the Licensed
Patents, and IGR&D may, for such purposes, join Omnimmune as a party
plaintiff at IGR&D's sole cost and expense.  The total cost of any
such infringement action commenced solely by IGR&D shall be borne by
IGR&D and IGR&D shall allocate and distribute, in accordance with the
methodology referenced in Section 8(a)(ii) above, any recovery or damages for
past infringement derived therefrom that remains after reimbursement of any
costs of litigation (including negotiation and settlement proceedings) relating
thereto that has been incurred by IGR&D and Omnimmune.

     

    
      	
              b.  

            	
              Infringing Rights of
      Third Parties.  Each Party shall promptly notify the
      other Party if any legal proceedings are commenced or threatened against
      either Party or any purchaser of a Licensed Product or Licensed Process
      sold by Omnimmune on the grounds that the manufacture, use, sale or
      possession thereof is an infringement of a Third Party’s patent or other
      intellectual property rights.  Omnimmune shall, at its own
      expense, defend all suits brought against it as a result of the exercise
      of the rights granted hereunder, and IGR and IGR&D shall, at the
      request and expense of and when requested by Omnimmune, give Omnimmune all
      reasonable assistance in any such
proceedings.

            

    

     

    
      	
              c.  

            	
              Sublicensing
      Agreements with Infringer.  Omnimmune shall, during the
      exclusive period of this Agreement, have the sole right subject to the
      terms and conditions hereof to sublicense to any alleged infringer for
      future use of the Licensed Patents to the extent licensed by this
      Agreement.  Any upfront fees paid to Omnimmune as part of such a
      sublicense, after reimbursement of any legal expenses incurred by
      Omnimmune, shall be treated as Sublicense Revenues for purposes of this
      Agreement.

            

    

     

    
      	
              d.  

            	
              Cooperation.  In
      the event one Party shall initiate or carry on legal proceedings to
      enforce or defend any Licensed Patent against a Third Party, the other
      Party shall use its best commercially reasonable efforts to cooperate
      fully with and shall supply all assistance reasonably requested by the
      Party initiating or carrying on such
  proceedings.

            

    

     

    
      	
              9.  

            	
              No
      Warranty.  EXCEPT AS SET FORTH IN THIS AGREEMENT,
      IGR&D MAKES NO WARRANTIES EXPRESSED OR IMPLIED OF ANY KIND, AND HEREBY
      EXPRESSLY DISCLAIMS ANY WARRANTIES, REPRESENTATIONS OR GUARANTIES OF ANY
      KIND AS TO LICENSED TECHNOLOGY OR ANYTHING DEVELOPED, MANUFACTURED, USED,
      SOLD, RENTED, LEASED OR OTHERWISE DISPOSED OF UNDER ANY LICENSE GRANTED
      UNDER THIS AGREEMENT, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF
      MERCHANTABILITY, TITLE OR FITNESS FOR A PARTICULAR PURPOSE OR RESULT OF
      USE; ANY WARRANTIES OR REPRESENTATIONS AS TO THE VALIDITY OF ANY LICENSED
      PATENT; AND ANY WARRANTIES OF FREEDOM OF INFRINGEMENT OF DOMESTIC OR
      FOREIGN PATENTS, COPYRIGHTS, TRADE SECRETS, TRADEMARKS, KNOW HOW OR ANY
      OTHER INTELLECTUAL OR PROPRIETARY RIGHTS OF THIRD
  PARTIES.

            

    

     

    
      	
              10.  

            	
               No
      Infringement.  On the Effective Date, neither IGR nor
      IGR&D has any knowledge that it is infringing upon any patent and
      neither IGR nor IGR&D has received any notice of any such
      infringement.

            

    

     

    
      	
              11.  

            	
              Prohibition
      Against Use of IGR&D’s Name.  Except as may be
      required by governmental authority or law, Omnimmune will not use the
      name, insignia, or symbols of IGR or IGR&D, its faculties or
      departments, or any variation or combination thereof, or the name of any
      trustee, faculty member, other employee, or student of IGR or IGR&D
      for any purpose whatsoever without IGR or IGR&D’s prior written
      consent, which consent shall not be unreasonably
  withheld.

            

    

     

    
      	
              12.  

            	
              Compliance
      with Governmental Obligations.  Omnimmune shall comply in
      all material respects upon reasonable notice from IGR&D with all
      reasonable governmental requests pertaining to the license hereunder or
      any Licensed Products or Licensed Processes that are directed to either
      IGR&D or Omnimmune and shall provide all information and assistance
      reasonably necessary to comply with reasonable governmental requests
      pertaining to the license hereunder or any Licensed Products or Licensed
      Processes.  Omnimmune shall insure that research, development
      and marketing under this Agreement complies in all material respects with
      all applicable government regulations in force and effect, including, but
      not limited to, federal, state, and municipal
  legislation.

            

    

     

    
      	
              13.  

            	
              Indemnity.  Omnimmune
      will indemnify, defend and hold each of IGR and IGR&D harmless from
      and against any and all actions, suits, claims, demands, prosecutions,
      liabilities, costs, and expenses (including reasonably and actually
      incurred attorneys’ fees) based on, arising out of, or relating to,
      directly or indirectly, this Agreement, including, without limitation
      (a) the development, manufacture, packaging, use, sale, rental, or
      lease of Licensed Products or Licensed Process, even if altered for use
      for a purpose not intended, (b) use of Licensed Technology by
      Omnimmune, its Affiliates, its sublicensees or its (or their) customers,
      (c) any representation made or warranty given by Omnimmune, its
      Affiliates or sublicensees to Third Parties with respect to the Licensed
      Technology, and (d) any infringement claims relating to Licensed
      Technology; provided, however, that
      this indemnification shall not extend to any claims arising out of any act
      or omission constituting: (1) a material breach of this Agreement by IGR
      or IGR&D; (2) a material violation by IGR, IGR&D, its directors,
      officers, employees or agents, of applicable law or other governmental
      requirement governing IGR or IGR&D; or (3) intentional or willful
      misconduct by IGR, IGR&D, its directors, officers, employees,
      contractors, agents or representatives; or (4) use by IGR, IGR&D or
      any employee thereof, of the Licensed Technology prior to the Effective
      Date or thereafter under or pursuant to Section 5 of this
      Agreement.

            

    

     

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              14.  

            	
              Confidentiality.

            

    

     

    
      	
              a.  

            	
              In
      General.  Except as may otherwise be agreed to in any
      subsequent agreement, each Party agrees that all Confidential Information
      disclosed by Disclosing Party to Recipient or its Designated
      Representatives (1) shall not be used for any purpose whatsoever by
      Recipient or its Designated Representatives, except in fulfillment of
      Recipient's rights or obligations under this Agreement, (2) shall be
      maintained in confidence by Recipient and its Designated Representative
      for the period described below, and (3) shall not be otherwise
      disclosed by Recipient or its Designated Representative to any other Third
      Party to this Agreement without Disclosing Party's prior written
      consent.  Notwithstanding the foregoing, Recipient may disclose
      Disclosing Party's Confidential Information if Recipient is required to
      make such disclosure by applicable law, regulation or legal process,
      including, without limitation, by the rules or regulations of the United
      States Securities and Exchange Commission or similar regulatory agency in
      a country other than the United States or of any stock exchange or NASDAQ,
      in which event Recipient shall provide prior notice of such intended
      disclosure to Disclosing Party if possible under the circumstances and
      shall disclose only such Confidential Information of such Disclosing Party
      as is required to be disclosed.

            

    

     

    
      	
              b.  

            	
              Designative
      Representatives.  The Recipient shall remain responsible
      for any failure by any such Designated Representative to treat such
      Confidential Information as required under this
    Section. 

            

    

     

    
      	
              c.  

            	
              Miscellaneous.  The
      obligations of confidentiality in this Agreement are binding for the term
      of this Agreement and a period of three (3) years from the date of
      termination of this Agreement; provided, however, that
      in the case of Confidential Information that constitutes a trade secret,
      such period of limitation shall run for the term of this Agreement and for
      such period thereafter, if longer, during which any such information
      continues to constitute a trade secret as defined under applicable law.
      This Section shall be construed as an agreement ancillary to the
      other provisions of this Agreement, and the existence of any claim or
      cause of action of one Party against the other, whether predicated on this
      Agreement or otherwise, shall not constitute a defense to the enforcement
      of this Section. All written documents containing Confidential
      Information, together with copies of excerpts thereof, shall promptly be
      returned to Disclosing Party by Recipient upon request following
      termination of this Agreement.  Notwithstanding anything to the
      contrary herein, any information, including information that may be
      considered to be part of the Invention, that is or becomes generally known
      to the public through no wrongful acts of Recipient shall not be deemed to
      be Confidential Information and shall not be subject to the
      confidentiality restrictions imposed under this
  Agreement.

            

    

     

    
      	
              15.  

            	
              Severability.  If
      any provision hereof should be held invalid, illegal or unenforceable in
      any respect, then, to the fullest extent permitted by law, (a) all
      other provisions hereof shall remain in full force and effect and shall be
      liberally construed in order to carry out the intentions of the Parties as
      nearly as may be possible and (b) the Parties shall use their best
      efforts to replace the invalid, illegal or unenforceable provision(s) with
      valid, legal and enforceable provision(s) which, insofar as practical,
      implement the purposes of such provision(s) in this
    Agreement.

            

    

     

    
      	
              16.  

            	
              Term
      of Agreement.

            

    

     

    
      	
              a.  

            	
              This
      Agreement shall be effective as of the Effective Date and shall continue
      in full force and effect until its expiration or termination in accordance
      with this Section.

            

    

     

    
      	
              b.  

            	
              Unless
      terminated earlier under any provision of this Agreement, the term of this
      Agreement shall extend until the later to occur of
  either:

            

    

     

    i. The
expiration of the last to expire of the Licensed Patents in any country in which
any such patent may have been issued; or

     

    ii. So long
as a Licensed Product or Licensed Process is available for sale based on or
derived from Know How that has not otherwise been made the subject of a public
disclosure or otherwise becomes available to the public other than pursuant to
the issuance of a Licensed Patent or Licensed Material, ten years from the date
of First Commercial Sale of any Licensed Product or Licensed Process produced
from such Licensed Patents.

     

    
      	
              c.  

            	
              The
      license granted under this Agreement may be terminated by Omnimmune at any
      time upon thirty days’ written notice to IGR&D; provided, however, that
      in no event shall any such termination obviate Omnimmune’s obligation to
      pay IGR&D any payments accrued through the date of
      termination.

            

    

     

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
               
      

            	
              d.

            	
              This
      Agreement may be terminated by either IGR&D or Omnimmune if the other
      Party (1) makes an assignment for the benefit of creditors, petitions or
      applies to any court or other tribunal for the appointment of a custodian,
      receiver, or trustee for it or a substantial part of its assets; (2)
      commences any proceeding under any bankruptcy, reorganization,
      arrangement, readjustment of debt, dissolution, or liquidation law or
      statute of any jurisdiction, whether now or hereafter in effect; (3) has
      any petition or application, or other proceeding, commenced against it
      (including, but not limited to, involuntary bankruptcy proceedings), in
      which an order for the appointment of a custodian, receiver or trustee for
      it or all or a substantial part of its assets is sought and in which the
      requested relief is substantially granted or adjudication or appointment
      is made, and which proceeding, petition or application remains undismissed
      for a period of not more than (30) thirty days; (4) by any act or omission
      indicates its consent to, approval of, or acquiescence in any petition,
      application, or proceeding under  any bankruptcy,
      reorganization, arrangement, readjustment of debt, dissolution or
      liquidation law, or its consent to, approval of, or acquiescence in any
      petition, application or proceeding for the appointment of a custodian,
      receiver, or trustee for all or any substantial part of its properties; or
      (5) is subject to third-party custodianship, receivership, or trusteeship
      for a period of not more than thirty (30)
days.

            

    

    

    
      	
               
      

            	
              e.

            	
              Failure
      by any Party to substantially comply with any respective material
      obligation or condition contained in this Agreement shall entitle
      Omnimmune (in the case of such a default by either IGR or IGR&D) or
      IGR&D (in the case of such a default by Omnimmune) to give to the
      Party in default notice requiring it to cure such default.  If
      such default is not cured within ninety (90) days after receipt of such
      notice by the defaulting Party, the notifying Party shall be entitled
      (without prejudice of any of its other rights conferred on it by this
      Agreement) to terminate this Agreement by giving termination notice to
      take effect immediately; provided, however, that
      notwithstanding the foregoing, if in the event the defaulting Party
      disputes an alleged Default claimed as to any matter other than for the
      failure to pay an amount during and owing under Section 3 of this
      Agreement (a “Nonmonetary Default”), then such cure period shall be tolled
      for the period during which any such dispute of a Nonmonetary
      Default  remains pending before any judicial tribunal or
      arbitrator and this Agreement shall remain in full force and
      effect.  Should it be finally determined that the defaulting
      Party was in Default under this Agreement for such a NonMonetary Default,
      then such defaulting Party shall have the remainder of the cure period to
      cure the same.  Any notice of Default shall state the nature of
      the defaults claimed by the non-breaching party.  Subject to the
      forgoing, the defaulting Party during said ninety (90) day period, or such
      longer period as may be indicated by the Nondefaulting Party, may correct
      any default stated in said notice and if such default is corrected, this
      Agreement shall continue in full force and effect as if such notice had
      not been given.  An Affiliate or Sublicensee shall have the
      right to cure any Default by Omnimmune.  The right of either
      such Party to terminate this Agreement as provided in this Section shall
      not be affected in any way by its waiver of, or failure to take action
      with respect to any previous default. This provision shall not be
      interpreted as as waiver of any claim of damages in
  court.

            

    

    

    
      	
               
      

            	
              f.

            	
              Upon
      any termination of this Agreement, all sublicenses granted by Omnimmune
      hereunder shall be assigned to
IGR&D.

            

    

     

    
      	
               
      

            	
              g.

            	
              Sections 1,
      2(b), 2(d),  4, 14, 16, 17, 18, 20 and 21 shall survive the
      termination or expiration of this
Agreement.

            

    

     

    
      	
              17.  

            	
              Notices.  Any
      notice required or permitted to be given under this Agreement shall be
      sufficient if sent by certified mail (return receipt requested), postage
      pre-paid, if

            

    

     

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              if
      to IGR, to

            	
              [Contact
      Person

              Address]

               

               

               

               

            
	
              if
      to IGR&D, to:

            	
              Isabelle
      Pelletier Bressac

              General
      Manager

              IGR&D
      S.A.

              39
      rue Camille Desmoulins

              94800
      VILLEJUIF

              FRANCE

              Fax
      : + 33 1 42 11 6085

            
	 
      	 
      
	 
      	 
      
	
              if
      to Omnimmune, to:

            	
              Harris A.
      Lichtenstein, Ph.D.

              President &
      CEO

              Omnimmune
      Corp.

              4600
      Post Oak Place

              Suite
      352

              Houston,
      Texas 77027

               

            
	 
      	 
      
	
              with
      a copy to:

            	
              Frank
      McDaniel, Esq.

              Dinur,
      McDaniel, DeLuca & Henry, LLP

              PO
      Box 681235

              Marietta,
      Georgia   30068-0021

              404.393.5916
      fax

              frank.mcdaniel@lawmsh.com

               

            

    

    or to
such other address as a Party may specify by notice hereunder.

     

    
      	
              18.  

            	
              Force
      Majeure.  Any delays in or failures of performance by
      either Party under this Agreement shall not be considered a breach of this
      Agreement if and to the extent caused by occurrences beyond the reasonable
      control of the Party affected, including, but not limited to, acts of god;
      acts regulations, or laws of any government (including, without
      limitation, drug, pharmaceutical, device, import and export regulations);
      strikes or other concerted acts of workers; fires; floods; explosions;
      riots; wars; rebellion and sabotage; and any time for performance
      hereunder shall be extended by the actual time of delay cause by such
      occurrence.  Each Party shall promptly give notice to the other
      of any such failure or delay and shall provide a reasonable estimate of
      its expected duration.

            

    

     

    
      	
              19.  

            	
              Assignment.  This
      Agreement shall be binding upon and inure to the benefit of the Parties
      and their respective permitted successors and permitted
      assigns.  This Agreement may not be assigned by either Party
      without the prior written consent of the other Party, which consent shall
      not be unreasonably withheld; provided, however, that
      Omnimmune may assign this Agreement by operation of law, whether by merger
      or otherwise, or sale of all or substantially all of its
      assets.  IGR&D may assign IGR&D’s rights to receive
      royalties payable pursuant to this Agreement without the consent of
      Omnimmune.

            

    

     

    
      	
              20.  

            	
              Entire
      Agreement.  This Agreement constitutes the entire
      understanding by and between the Parties with respect to the subject
      matter hereof, and supersedes and replaces all prior agreements,
      understandings, writings, and discussions between the Parties relating to
      said subject matter.

            

    

     

    
      	
              21.  

            	
              Governing
      Law.  This Agreement shall be governed by USA law
      applicable to agreements made and to be fully performed in the State of
      Texas, except as to Confidential Information and the restrictions relating
      thereto, which shall be governed by the laws of the State of Texas, USA in
      the case where Omnimmune is the Disclosing Party, and by the laws of the
      Republic of France in the case where IGR or IGR&D is the Disclosing
      Party.  In the event a dispute should arise, the Parties agree
      to attempt to settle their differences out of court.  In case
      they are unable to resolve any such dispute amongst themselves, then if
      the defendant is Omnimmune, the disagreement shall be taken before the
      competent courts located in Houston, Texas, USA; if the defendant is IGR
      or IGR&D, the disagreement shall be taken before the competent French
      courts.

            

    

     

    
      	
              22.  

            	
              Export
      Control Laws.  This Agreement is made subject to any
      restrictions concerning the export of products or technical information
      from the United States of America which may be imposed from time to time
      by the government of the United States of America.  Furthermore,
      each Party hereto agrees that it will not export, directly or indirectly,
      any technical information acquired from the other under this Agreement or
      any products using such technical information to any country for which the
      United States government or any agency thereof at the time of export
      requires an export license or other governmental approval, without first
      obtaining the written consent to do so from the Department of Commerce or
      other agency of the United States government when required by an
      applicable statute or regulation.

            

    

     

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    IN WITNESS THEREOF, IGR&D
and Omnimmune have caused this Agreement to be executed by their duly authorized
representatives as of the day and year written below.

     

    
      	 
      	
              IGR

            
	 
      	 
      
	 
      	
              Institut
      Gustave Roussy

            
	 
      	 
      
	 
      	 
      
	 
      	
              By:  /s/                                                                    

            
	 
      	 
      
	 
      	 
      
	 
      	 
      
	 
      	 
      
	 
      	
              IGR&D,
      à Villejuif le 26 Octobre 2007

            
	 
      	 
      
	 
      	
              IGR&D,
      SA

            
	 
      	 
      
	 
      	
              By:  /s/ Isabelle Pelletier
      Bressac                         

            
	 
      	
              Isabelle
      Pelletier Bressac

              General
      Manager

            
	 
      	 
      
	 
      	 
      
	 
      	
              OMNIMMUNE

            
	 
      	 
      
	 
      	
              Omnimmune
      Corp.

            
	 
      	 
      
	 
      	
              By: /s/
      Harris A. Lichtenstein                                  

            
	 
      	
                    Harris A.
      Lichtenstein, Ph.D.

                    President &
      CEO

            
	 
      	 
      

    

     

     

    
 

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    ATTACHMENT
A

     

    LICENSED
PATENTS:

     

    
      	
              1.  

            	
              Malignant
      human cell transformation detection method, U.S. Patent No. 6,194,154,
      issued 27 February, 2001

            

    

     

    
      	
              2.  

            	
              Process
      for detecting the malignant transformation of human cells, U.S. Patent No.
      6,514,708, issued 4 February, 2003

            

    

     

    LICENSED MATERIALS AND
LICENSED PROCESSES:

     

    
      	
              1.  

            	
              Any
      and all antibodies or antibody cell lines referred to in the claims of the
      Licensed Patents or otherwise relating
thereto.

            

    

     

    
      	
              2.  

            	
              Any
      and all hCG protein (or epitopes) referred to in the claims of the
      Licensed Patents or otherwise relating
thereto.

            

    

     

    
      	
              3.  

            	
              Any
      and all hCG genetic sequences referred to in the claims of the Licensed
      Patents or otherwise relating
thereto.

            

    

     

    
      	
              4.  

            	
              All
      formulae, algorithms or data management or interpretive systems, including
      or otherwise related to the CG117 Assay and related Transformation
      Index.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}]]